Galderma H1 FY26 net income jumps 128.87% to USD 444 million; net sales climb 24.6% to USD 3.13 billion

(AWP Alliance News) - Galderma posted first-half 2026 net sales of USD 3.13 billion, up 28% year on year on a reported basis, as IFRS net income climbed to USD 444 million from USD 194 million. Core EBITDA rose to USD 802 million from USD 555 million, lifting the Core EBITDA margin to 25.6% from 22.7%.

Therapeutic Dermatology net sales jumped to USD 848 million from USD 489 million, driven by Nemluvio net sales of USD 433 million from USD 131 million. The group raised its 2026 net sales growth guidance to 19%-21% at constant currency, confirming a Core EBITDA margin of about 26% at constant currency.

https://www.businesswire.com/news/home/20260722555754/en/

Disclaimer: This news brief was created using generative artificial intelligence. Galderma Group AG published the original content used to generate this news brief via Business Wire on July 23, 2026, and is solely responsible for the information contained therein.